A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania

Persistence to Treatment With Guselkumab in Bio-Naive Patients With Moderate-to-Severe Plaque Psoriasis: A Romanian Non-Interventional Multi-center Observational Study

This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.

Inclusion criteria:

• Has a confirmed diagnosis of moderate-to-severe plaque psoriasis
• Participant must sign an informed consent form allowing source data verification in accordance with local requirements
• Is able to read, understand, and complete the patient reported outcomes (PRO) instruments in local language and comply with completion of all PRO instruments
• No previous exposure to biological treatment, including guselkumab (bio-naive patient)
• Intended for the treatment with guselkumab according to the approved indication

Exclusion criteria:

• Meets any of the contraindications according to the latest version of the locally approved summary of product characteristics (SmPC)
• Is pregnant or lactating
• Current or recent (in the last 30 days prior to first SC dose of guselkumab) participation in any interventional study with investigational product.
• Currently enrolled in another observational study sponsored or managed by a Johnson & Johnson company